The effect of itracameral bevacizumab injection on outcome of trabeculectomy

Intracameral Bevacizumab and Trabeculectomy Versus Trabeculectomy With Mitomycin C Alone for Open Angle Glaucoma: A clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014042617443N1

Enrollment

Registered

2014-08-04

Start date

2013-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open angel glaucoma. Primary open-angle glaucoma

Interventions

Intervention 1: trabeculectomy adjunctive with 1.25mg per 0.05 ml intracameral bevacizumab. Intervention 2: trabeculectomy adjunctive with 0.2 mg mitimycine c under conjuctival and scleral flap.

Treatment - Surgery

trabeculectomy adjunctive with 1.25mg per 0.05 ml intracameral bevacizumab

trabeculectomy adjunctive with 0.2 mg mitimycine c under conjuctival and scleral flap

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: primary openagle glaucoma candidate for trabeculectomy; pseudoexfoliative glaucoma candidate for trabeculectomy Exclusion criteria: age<50 ; high risk patients for cardiovascular disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Intraocular pressure. Timepoint: before intervention,1 week, 1 month, 3 month and 6 months after intervention. Method of measurement: Goldman aplanation tonometer.	—

Secondary

Measure	Time frame
Bleb morphply. Timepoint: 3 and 6 months after intervention. Method of measurement: morphild grading system.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Mafi

Farabi eye hospital

mostafa.mafi17@gmail.com+98 21 6691 9709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026